Skip to content

Treatment of Chronic Insomnia According to Yin Yang Theory and Its Correlation With Circadian Rhythm

Clinical Normative Evaluation of Chronic Insomnia Treated by Traditional Chinese Medicine According to Yin Yang Theory and Its Correlation With Circadian Rhythm

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05452577
Enrollment
187
Registered
2022-07-11
Start date
2021-01-22
Completion date
2023-05-30
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Insomnia, Circadian Rhythm, Traditional Chinese Medicine

Brief summary

The purpose of this study is to assess the safety and efficacy of Traditional Chinese medicine (TCM) according to Yin Yang theory for treatment of chronic insomnia .

Detailed description

All subjects giving written informed consent. In this multicenter, controlled, prospective cohort study, the outpatient and inpatient chronic insomnia patients' baseline demographic data were collected, including age, gender, education background, and medication history. Venous blood samples were collected and sent to laboratory test for blood routine, and blood biochemistry at Baseline and Week 4. The Pittsburgh sleep quality index (PSQI) was used to assess the patients' sleep quality at baseline and week 4. Objective sleep quality data is assessed by wearing a Sleep wearable devices. The classic Morningness-Eveningness Questionnaire and wearable devices was used to assess the patients' chronotype at baseline and week 4.Subjects who visit the TCM clinic of this project received Suanzaoren Decoction and Huanglian Wendan Decoction orally twice daily for 4 weeks. Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient. Subjects from TCM clinic who had previously taken Western medicine hypnotics continued taking them, and for those who had not taken before, Western medicine hypnotics shall not be given/prescribed. Subjects who visit the Western medicine clinic of this project received Estazolam 1mg tablet orally once daily for 4 weeks. The participants will have a follow-up visit every two weeks, and the prescription would be adjusted according to the condition of illness.Cessation rate of Western medicine hypnotics was assessed at Month 6.

Interventions

Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.

DRUGEstazolam 1Mg Tab

1mg tablet once daily

Sponsors

The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Outpatients or inpatients. * It conforms to the chronic insomnia diagnosis standard of Chinese adult insomnia diagnosis and treatment guide (2017 Edition). * Chronic insomnia patients with Yin yang imbalance and Ying Wei Disharmony Syndrome. * Informed consent, voluntary participation in the study.

Exclusion criteria

* Sleep apnea syndrome leads to insomnia. * Severe depression, suicidal tendency or having committed suicide. * Pregnant and lactating women. * It has serious primary heart, liver, lung, kidney, blood or serious diseases affecting its survival, such as: tumor or AIDS, SCR \> 1.5n (n is the upper limit of normal value), ALT \> 2n (n is the upper limit of normal value), WBC \< 3.0 × 109 / L; * Those who cannot give full informed consent due to mental disorders. * According to the researcher's judgment, other situations that are not suitable for the group, such as the change of working environment. * Subjects who are participating in other clinical studies.

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline in the total score of the Pittsburgh sleep quality index (PSQI) at 4 weeksBaseline and Week 4The Pittsburgh sleep quality index (PSQI) is a validated,self-reported instrument assessing the sleep quality over the past 4 week period. Possible scores range from 0(the best sleep quality) to 21(the worst possible sleep) quality).The higher the score of PSQI, the worse the sleep quality. Change=(Month 1 Score-Baseline Score)
Cessation rate of Western medicine hypnotics at Month 6Month 6Cessation was defined as an absence of any Western medicine hypnotics that was sustained for 3 consecutive months or more. Cessation rate of Western medicine hypnotics=(Month 6 number-Baseline number)/Baseline number of Participants use Western medicine hypnotics.

Secondary

MeasureTime frameDescription
Change from Baseline of the BUN at 4 weeksBaseline and Week 4Blood urea nitrogen, BUN in mmol/L
Change from Baseline of the Scr at 4 weeksBaseline and Week 4Serum creatinine, Scr in μmol/L
Change from Baseline of the ALT at 4 weeksBaseline and Week 4Alanine aminotransferase, ALT in U/L
Change from Baseline in the score of Morningness-Eveningness Questionaire (MEQ)Baseline and Week 4The MEQ is a validated, self-reported questionaire assessing personal chronotype in the recent period. Possible scores range from 16 (extreme eveningness) to 86 (extreme morningness). Change = (Week 4 Score - Baseline Score). Positive score change indicates a shift from eveningness to morningness.
Change from baseline objective sleep qualityBaseline and Week 4Objective sleep quality data is assessed by wearing a Sleep wearable devices
Genome-wide association studyMonth 6Illumina HumanHap550-Duo BeadChips was used to perform the whole genome genotyping in deCODE genetics(Reykjavı'k, Iceland)
Change from Baseline of the AST at 4 weeksBaseline and Week 4Aspartate aminotransferase, AST in U/L

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026